# EDGAR Filing Document

**Accession Number:** 0001509261
**File Stem:** 0001104659-25-115050
**Filing Date:** 2025-11
**Character Count:** 7431
**Document Hash:** 795736604f3febf3687a12e99e060929
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-115050.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0001104659-25-115050

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251119

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251121

**DATE AS OF CHANGE**: 20251121

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rezolute, Inc.
- **CENTRAL INDEX KEY:** 0001509261
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 273440894
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39683
- **FILM NUMBER:** 251508826

**BUSINESS ADDRESS:**
- **STREET 1:** 275 SHORELINE DRIVE, SUITE 500
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-206-4507

**MAIL ADDRESS:**
- **STREET 1:** 275 SHORELINE DRIVE, SUITE 500
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AntriaBio, Inc.
- **DATE OF NAME CHANGE:** 20130114

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FITS MY STYLE INC
- **DATE OF NAME CHANGE:** 20110104

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): November 19, 2025**

**<u>REZOLUTE, INC.</u>**

**(Exact Name of Registrant as Specified in Charter)**

---

| | | |
|:---|:---|:---|
| <u>**<u>Nevada</u>**</u> | <u>**<u>001-39683</u>**</u> | <u>**<u>27-3440894</u>**</u> |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**<u>275 Shoreline Drive, Suite 500, Redwood City, CA 94065</u>**

**(Address of Principal Executive Offices, and Zip Code)**

**<u>650-206-4507</u>**

**Registrant's Telephone Number, Including Area Code**

**<u>Not Applicable</u>**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

◻ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.001 per share** | **RZLT** | **Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Rezolute, Inc. (the "**Company**") held its 2026 annual meeting of stockholders on November 19, 2025. The meeting was held virtually at www.virtualshareholdermeeting.com/RZLT2025. As of the record date, September 22, 2025, there were a total of 90,811,368 shares of common stock outstanding and entitled to vote at the special meeting. At the annual meeting, 66,700,068 shares of common stock were represented in person (virtually) or by proxy; therefore, a quorum was present. The final voting results for the matters submitted to a vote of stockholders were as follows:

**<u>Proposal No. 1 - Election of Directors</u>**

To elect the following nominees to serve as members of the Company's board of directors:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee Name** | **Votes For** | **Votes Withheld** | **Broker Non Votes** |
| Nevan Charles Elam | 59206610 | 161306 | 7332152 |
| Young-Jin Kim | 52980022 | 6387894 | 7332152 |
| Gil Labrucherie | 55354306 | 4013610 | 7332152 |
| Philippe Fauchet | 58711617 | 656299 | 7332152 |
| Nerissa Kreher, M.D. | 45487489 | 13880427 | 7332152 |
| Wladimir Hogenhuis, M.D. | 45753848 | 13614068 | 7332152 |
| Erik Harris | 48235273 | 11132643 | 7332152 |

---

**<u>Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm</u>**

To ratify Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending on June 30, 2026:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non Votes** |
| 65206245 | 937798 | 556025 |  |

---

**<u>Proposal No. 3 - Say-on-Pay Proposal</u>**

To approve by a non-binding advisory vote, the compensation of the Company's named executive officers, as disclosed in the Executive Compensation section of the proxy statement:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non Votes** |
| 40149598 | 19193827 | 24491 | 7332152 |

---

**<u>Proposal No. 4- Equity Plan Amendment Proposal</u>**

To approve an amendment to the Company's 2021 Stock Incentive Plan (the "**2021 Equity Plan Amendment Proposal**") to increase the number of shares available for issuance thereunder from 14,450,000 shares of common stock to an aggregate of 21,950,000 shares of common stock:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non Votes** |
| 59075559 | 264536 | 27821 | 7332152 |

---

**<u>Proposal No. 5 - Adjournment Proposal</u>**

To authorize an adjournment of the meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the 2021 Equity Plan Amendment Proposal:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non Votes** |
| 57909553 | 1423506 | 34857 | 7332152 |

---

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits. The following Exhibits are furnished as part of this Current Report on Form 8-K.

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **REZOLUTE, INC.** | **REZOLUTE, INC.** |
| DATE: November 21, 2025 | By: | */s/ Nevan Elam* |
|  |  | Nevan Elam |
|  |  | Chief Executive Officer |

---